📊 AXIM Key Takeaways
Is Axim Biotechnologies, Inc.. (AXIM) a Good Investment?
AXIM is in severe financial distress with negative stockholders' equity of -9.5M, liabilities exceeding assets by 9.6M, and a cash position of only 6K despite long-term debt of 6M. The company is burning cash at an accelerating rate (-514K operating cash flow) while generating minimal revenue (70.5K), rendering it technically insolvent and at critical risk of bankruptcy without immediate capital restructuring.
AXIM Biotechnologies shows a superficially strong revenue growth rate, but the base is extremely small and nowhere near enough to support the company’s cost structure. Fundamentals are severely impaired by persistent large losses, deeply negative margins, near-zero liquidity, negative equity, and ongoing cash burn, indicating very weak financial health and poor growth quality.
Why Buy Axim Biotechnologies, Inc.. Stock? AXIM Key Strengths
- Exceptional gross margin of 97.5% indicates strong unit economics on limited revenue
- Recent revenue growth of 345.3% YoY shows early commercial traction despite minimal absolute scale
- Pharmaceutical sector positioning may provide future revenue opportunities if operations stabilize
- Revenue grew 345.3% year over year, indicating some commercial activity improvement
- Gross margin of 97.5% suggests the product mix is high margin before overhead
- Capital expenditure is minimal, limiting additional fixed investment needs
AXIM Stock Risks: Axim Biotechnologies, Inc.. Investment Risks
- Negative stockholders' equity of -9.5M indicates technical insolvency and potential bankruptcy risk
- Liquidity crisis with current ratio 0.00x and cash balance of 6K insufficient to cover operations
- Severe cash burn of -514K operating cash flow with virtually no offsetting revenue generation
- Long-term debt of 6M creates refinancing risk given negative equity and operational losses
- Net losses of 2.6M on 70.5K revenue unsustainable; operating margins of -1378% indicate fundamental business model failure
- Zero insider activity in 90 days suggests potential loss of confidence from management
- Cash of only $6.04K and current ratio of 0.00x indicate acute liquidity stress
- Negative stockholders’ equity of $-9.53M and $13.26M in liabilities reflect a highly impaired balance sheet
- Operating loss of $971.01K and free cash flow of $-516.89K show the business is far from self-funding
Key Metrics to Watch
- Stockholders equity trend and timeline to recapitalization or restructuring
- Monthly revenue run rate and path to breakeven on operating expenses
- Cash position and runway remaining given -514K monthly cash burn
- Debt refinancing ability and covenant compliance status
- Quarterly operating cash flow for sustainability assessment
- Quarterly revenue growth relative to operating expenses
- Cash runway and any improvement in working capital or stockholders’ equity
Axim Biotechnologies, Inc.. (AXIM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AXIM Profit Margin, ROE & Profitability Analysis
AXIM vs Healthcare Sector: How Axim Biotechnologies, Inc.. Compares
How Axim Biotechnologies, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Axim Biotechnologies, Inc.. Stock Overvalued? AXIM Valuation Analysis 2026
Based on fundamental analysis, Axim Biotechnologies, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Axim Biotechnologies, Inc.. Balance Sheet: AXIM Debt, Cash & Liquidity
AXIM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Axim Biotechnologies, Inc..'s revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
AXIM Revenue Growth, EPS Growth & YoY Performance
AXIM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $9.9K | -$292.3K | $-0.01 |
| Q1 2024 | $7.4K | -$292.3K | $0.00 |
| Q3 2023 | $1.3K | $328.5K | $0.00 |
| Q2 2023 | $9.9K | -$1.2M | $-0.01 |
| Q1 2023 | N/A | -$2.1M | $-0.01 |
| Q2 2022 | N/A | -$864.5K | $-0.01 |
| Q1 2022 | N/A | -$864.5K | $-0.01 |
| Q3 2021 | N/A | -$79.4K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Axim Biotechnologies, Inc.. Dividends, Buybacks & Capital Allocation
AXIM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Axim Biotechnologies, Inc.. (CIK: 0001514946)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AXIM
What is the AI rating for AXIM?
Axim Biotechnologies, Inc.. (AXIM) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AXIM's key strengths?
Claude: Exceptional gross margin of 97.5% indicates strong unit economics on limited revenue. Recent revenue growth of 345.3% YoY shows early commercial traction despite minimal absolute scale. ChatGPT: Revenue grew 345.3% year over year, indicating some commercial activity improvement. Gross margin of 97.5% suggests the product mix is high margin before overhead.
What are the risks of investing in AXIM?
Claude: Negative stockholders' equity of -9.5M indicates technical insolvency and potential bankruptcy risk. Liquidity crisis with current ratio 0.00x and cash balance of 6K insufficient to cover operations. ChatGPT: Cash of only $6.04K and current ratio of 0.00x indicate acute liquidity stress. Negative stockholders’ equity of $-9.53M and $13.26M in liabilities reflect a highly impaired balance sheet.
What is AXIM's revenue and growth?
Axim Biotechnologies, Inc.. reported revenue of $70.5K.
Does AXIM pay dividends?
Axim Biotechnologies, Inc.. does not currently pay dividends.
Where can I find AXIM SEC filings?
Official SEC filings for Axim Biotechnologies, Inc.. (CIK: 0001514946) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AXIM's EPS?
Axim Biotechnologies, Inc.. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AXIM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Axim Biotechnologies, Inc.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AXIM stock overvalued or undervalued?
Valuation metrics for AXIM: ROE of N/A (sector avg: 15%), net margin of -3,636.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AXIM stock in 2026?
Our dual AI analysis gives Axim Biotechnologies, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AXIM's free cash flow?
Axim Biotechnologies, Inc..'s operating cash flow is $-514.0K, with capital expenditures of $2.8K. FCF margin is -733.6%.
How does AXIM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,636.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).